» Articles » PMID: 15762276

Immunohistochemistry of Estrogen and Progesterone Receptors Reconsidered: Experience with 5,993 Breast Cancers

Overview
Specialty Pathology
Date 2005 Mar 15
PMID 15762276
Citations 152
Authors
Affiliations
Soon will be listed here.
Abstract

Paraffin sections or fine-needle aspiration smears from 5,993 cases of invasive mammary carcinomas were assessed immunohistochemically for estrogen receptor (ER; 1D5) and progesterone receptor (PR; 636) expression. Staining pattern and intensity were correlated with histologic subtypes and nuclear grades of tumors. Positive nuclear staining for ER and PR was observed in 75% and 55% of invasive carcinomas, respectively. In 92% of ER+ cases, diffuse and uniform staining of most tumor cells was observed. In the remaining 8%, a focal ER reaction was seen, usually because of inadequate fixation. In 21% of PR+ tumors, the reaction was heterogeneous or focal but unrelated to fixation. There were no ER-, PR+ tumors. All pure tubular, colloid, and infiltrating lobular carcinomas were ER+. All medullary, apocrine, and metaplastic and most high-nuclear-grade carcinomas were ER-. With monoclonal antibody 1D5 and antigen retrieval, immunohistochemical reaction for ER in breast cancer usually is an all-or-none phenomenon; therefore, quantitation of results is unnecessary. Despite antigen retrieval, inadequate fixation can cause false-negative results; evaluation of internal positive control samples is imperative. ER positivity and negativity are predictable in certain histologic types and nuclear grades of breast cancer. The reaction for PR can be heterogeneous or focal.

Citing Articles

Breast acinic cell carcinoma with weak progesterone receptor expression: a case report and literature review.

Bai C, Xin X, Yang Y, Qu F, Fan Z Front Oncol. 2025; 14:1497272.

PMID: 40051607 PMC: 11883444. DOI: 10.3389/fonc.2024.1497272.


Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy.

Howell S, Howell A Adv Exp Med Biol. 2025; 1464():449-474.

PMID: 39821038 DOI: 10.1007/978-3-031-70875-6_22.


Impact of CCND1 amplification on the prognosis of hormone receptor-positive, HER2-negative breast cancer patients-correlation of clinical and pathological markers.

Hanf D, Fasching P, Gass P, Beckmann M, Hack C, Heindl F Breast Cancer Res Treat. 2024; 210(1):125-134.

PMID: 39586971 PMC: 11787164. DOI: 10.1007/s10549-024-07545-x.


Renal pelvic plasmacytoid subtype urothelial carcinoma accompanied with solitary mammary metastasis.

Matsubara K, Hayakawa N, Aida K, Koike J, Kikuchi E Int Cancer Conf J. 2024; 13(3):296-300.

PMID: 38962031 PMC: 11217202. DOI: 10.1007/s13691-024-00681-7.


EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells.

Achounna A, Ordaz-Rosado D, Garcia-Quiroz J, Morales-Guadarrama G, Milo-Rocha E, Larrea F Int J Mol Sci. 2024; 25(6).

PMID: 38542136 PMC: 10970597. DOI: 10.3390/ijms25063165.